Traditional Rituximab infusion takes 2‑4 hours in a hospital chair. Subcutaneous (SC) Rituximab takes 5‑7 minutes — and can be given in a clinic or even at home. The rituximab market forecast shows that SC is the fastest‑growing route of administration, with a CAGR above 8%. Why the shift? Because patients want to spend less time in hospitals and more time living their lives.

How does it work? A fixed dose of Rituximab is injected under the skin, often using a pre‑filled syringe or auto‑injector. The rituximab market analysis notes that the fastest‑growing dosage form is infusion, but injection is catching up — because SC is so much faster.

But SC Rituximab isn't for everyone. It requires a higher concentration of the drug, which can cause injection site reactions. And it's not yet approved for all indications (CLL, rheumatoid arthritis).

The takeaway: if you're a patient receiving Rituximab, ask your oncologist about the subcutaneous version. It could free up hours of your time. And if you're a clinic, offering SC Rituximab can increase patient throughput.